Abs 0412 by @Spondy_MD et al at #ACR22: BKZ tx showed meaningful improvements in physical function and HRQoL in nr-axSpA and AS pts with consistent responses. @RheumNow https://t.co/diGqpQKfpS https://t.co/1pdGi47IJM

• Bimekizumab Improves Physical Function and Health-Related Quality of Life in Pa…

Another study showing treatment withdrawal does not work. Golimumab withdrawal in nr-axSpA is inferior to continued treatment or tapered treatment, leading to more disease flares. Abs#0545 @RheumNow #ACR22 https://t.co/CBRnVdxXVo

2022 ASAS-EULAR recommendation lit review in Abs 0413 at #ACR22 shows new evidence on education & exercise and confirms efficacy in axSpA. Tofa, UPA, FIL have shown efficacy in r-axSpA. @RheumNow https://t.co/8E9RZQ8Gz4 https://t.co/5QPO5eddFH

• Efficacy and Safety of Non-Pharmacological and Non-Biological Therapy: A System…

Interesting findings from Abs 0417 - when early axSpA is defined by duration of symptoms, only nr-axSpA tx w/ bDMARDs may lead to better outcomes vs early or established axSpA. #ACR22 @RheumNow https://t.co/8aGdyJRvv1 https://t.co/chAEGPicPd

• Treating Spondyloarthritis Early: Does It Matter? Results from a Systematic Lit…

NSAIDs plus TNFi (celecoxib and golimumab) therapy in ankylosing spondylitis did not show significant decrease in radiographic progression compared to TNFi monotherapy. *Numerical reduction in syndesmophytes 11% vs. 25% Abs#0546 @RheumNow #ACR22 #ACRBest https://t.co/pG5F3xdsh9

Abs 0419 SELECT-AXIS 2, UPA improved outcomes vs PBO in nr-axSpA pts across all BL inflammation subgroups; greatest benefit obs in pts with both elevated CRP and inflammation on baseline MRI. #ACR22 @RheumNow https://t.co/opaFwXgcvU https://t.co/o27ULcL8Ip

• Efficacy of Upadacitinib in Patients with Non-Radiographic Axial Spondyloarthri…

#Abstr 0545 GO-BACK Trial Continue vs Withdrawal of GOL in nr-axSpA with inactive disease - Full tx withdrawal associated w/ dx flare - Re-treatment -->rapid clinical response after flare - qMonthly tx --> higher rates of disease activity improvement @RheumNow #ACR22 https://t.co/Z3bhA9D4RQ

#ACR22 Abs 0408 @philipcrobinson et al, nr-axSpA pts achieving long-term clinical outcomes w/ CZP tx after 1 yr were generally sustained over 3 yrs across MRI+/CRP+, MRI−/CRP+ and MRI+/CRP− subgroups; ASDAS-MI numerically highest in MRI+/CRP+. @RheumNow https://t.co/cjpp2qCN4O https://t.co/G2YjF6ubUf

• Long-Term Clinical Outcomes of Certolizumab Pegol Treatment in Patients with Ac…

Potential disconnect: Objective Inflammatory Response, OIR (MRI/CRP levels) vs Clinical Response,CR (BASDAI/ASDAS). Post hoc analysis AxSpA on Certolizumab. Majority of patients >50% improved OIR, only minority improved CR. Rudwaleit etal https://t.co/WdkmkCWClO #ACR22 @RheumNow https://t.co/qlNUFhnuJQ

• An Exploratory Analysis of the Potential Disconnect Between Objective Inflammat…

2022 ASAS-EULAR Recommendations of AxSpA management 1) NSAIDs still first line 2) Analgesics/opioids contraindicated 3) TNFi, IL-17i first line bDMARDs, followed by JAKinibs 4) Tapering but not discontinuation of bDMARDs in sustained remission Abs#0542 @RheumNow #ACR22 https://t.co/ffaN2fMc3v

#Abstr 0542 ASAS EULAR Recommendations for Management of axSpA 'Absence of response to treatment should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities.' @RheumNow #ACR22

Liew @rheum_cat et al. No evidence of cardioprotective effect of early initiation of TNFi in AxSpA. In fact seemed to be associated higher risk! CVD (HR 1.17), stroke (HR 1.24), and MACE (HR 1.22) @rheumnow #ACR22 Abstr#0415 https://t.co/a9lpxQuMB9 https://t.co/GdGfYxcAH6

• The Association of Early TNF Inhibitor Use with Incident Cardiovascular Events …

Maguire et al @Sineadm15 @bososhea Stronger relationship between disease activity and QoL in men than women with AxSpA. Our current tools may be inadequate to fully evaluate women with AxSpA @rheumnow #ACR22 Abstr#0406 https://t.co/duHqO0DXh3 https://t.co/yRcFiNpujT

• Are the BASDAI & BASFI Capturing the Full Impact of Disease Activity on Qua…

Tofactinib efficacy for treatment of ankylosing spondylitis comparable across different BMI's. Regardless of BMI, tofacitinib better than placebo. BMI <25: more AE and SAE Abs#0405 @RheumNow #ACR22 https://t.co/qs3U4mjUXD

Rates of MACE and VTE with upadacitinib were infrequent and consistent with background rates in RA, PsA and AS patients. Factors associated with MACE/VTE: age>65, HTN, DM, smoking, history CV event/VTE Abs#0510 @RheumNow #ACR22 https://t.co/AjtJF0p3QK